Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799185 | 0.85 | ALOX5 (0.43) | NPC1RAB9AHSP90AA1AGTR1PAX8 | |
| SCHEMBL3079350 | 0.79 | RAB9A (0.40) | APPNPC1RAB9AHSP90AA1AGTR1 | |
| SCHEMBL8026472 | 0.77 | RARB (0.46) | RAB9AMAPTKDM4ECYP1A2CYP2C9 | |
| SCHEMBL5517928 | 0.75 | ALOX5 (0.44) | NPC1RAB9AHSP90AA1AGTR1PAX8 | |
| Diphenylacetylene SCHEMBL29188592 | 0.74 | APP (1.00) | APPNPC1RAB9AMAPTGRM5 | |
| Diphenylacetylene SCHEMBL960609 | 0.74 | APP (1.00) | APPNPC1RAB9AMAPTGRM5 | |
| Diphenylacetylene SCHEMBL68254 | 0.74 | APP (1.00) | APPNPC1RAB9AMAPTGRM5 | |
| SCHEMBL18752322 | 0.72 | SMN1; SMN2 (0.36) | NPC1RAB9AGRM5KDM4EALDH1A1 | |
| SCHEMBL11272511 | 0.72 | RAB9A (0.40) | NPC1RAB9AHSP90AA1AGTR1PAX8 | |
| SCHEMBL1048506 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| CN-117466695-A | Cobalt-catalyzed alkyne synthesis method | 合肥工业大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20150340612-A1 | UV EMITTERS COMPRISING A MULTIPLE BOND | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150340612-A1 | UV EMITTERS COMPRISING A MULTIPLE BOND | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| CN-103254065-B | 2,4,4',6-tetracarboxylic acid biphenyl silver complex and preparation method and application thereof | UNIV LUOYANG NORMAL | 2014-11-26 | — | — | CN | disclosed |
| WO-2014106520-A1 | UV EMITTERS COMPRISING A MULTIPLE BOND | MERCK PATENT GMBH (DE) | 2014-07-10 | — | — | WO | disclosed |
| CN-103254065-A | 2,3,4',6-tetracarboxylic acid biphenyl silver complex and preparation method and application thereof | UNIV LUOYANG NORMAL | 2013-08-21 | — | — | CN | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090233962-A1 | Amide derivative and insecticide containing the same | MITSUI CHEMICALS, INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7105707-B2 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | PHARMACORE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050137402-A1 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | DSM N.V. (NL) | 2005-06-23 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-5374701-A | Crosslinkable polymers of high strength free of structural defects | HAY ALLAN S (CA) | 1994-12-20 | — | — | US | disclosed |
| US-5233046-A | DIARYLACETYLENES, ENAMINES AND ACETYLENIC POLYMERS AND THEIR PRODUCTION | HAY ALLAN S (CA) | 1993-08-03 | — | — | US | disclosed |
| WO-1993009079-A1 | DIARYLACETYLENES, ENAMINES AND ACETYLENIC POLYMERS AND THEIR PRODUCTION | HAY ALAN S (CA) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | APP 614/4885NPC1 806/4885RAB9A 1607/4885 |
| US-20090233962-A1 | Amide derivative and insecticide containing the same | CYP1A1, CYP4B1, CYP2E1 | APP 900/4885NPC1 2896/4885RAB9A 1871/4885 |
| US-20050137402-A1 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | NAT1, B3GNT2, NISCH | APP 1495/4885NPC1 1680/4885RAB9A 2413/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | APP 614/4885NPC1 806/4885RAB9A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.